Published in Hepatitis Weekly, May 22nd, 2006
"Cyclosporin A (CsA) inhibits the in vitro replication of HCV subgenomic replicons. We here report on the potent anti-HCV activity of the non-immunosuppressive cyclosporin DEBIO-025," wrote J. Paeshuyse and colleagues, Rega Institute.
"The 50% effective concentration for inhibition of HCV subgenomic replicon replication in Hub 5-2 cells (luciferase assay) by DEBIO-025 was 0.27±0.03 mcg/mL and for CsA 2.8±0.4 mcg/mL. The concentration that reduced the growth of exponentially proliferating Hub 5-2 cells by 50% was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.